89bio, Inc. (ETNB) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Francisco, CA, 미국. 현재 CEO는 Rohan Palekar.
ETNB 을(를) 보유 IPO 날짜 2019-11-11, 93 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $2.2B.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
